Browse Category

Solutions - Page 11

New Medical Solutions curates credible advances that solve real problems in healthcare—faster diagnosis, safer procedures, better monitoring, smoother coordination, and fairer access.

Decision Criteria for Technology Commercialization of Medical Devices in 2026

The successful commercialization of innovative medical technologies remains a cornerstone of advancing healthcare delivery and patient outcomes. The journey from a novel concept to a market-ready product is fraught with complexity, requiring

February 26, 2026

Solutions

Viatris to cut 10% of workforce in 3-year overhaul, discloses fire at India plant

Viatris’ three-year reorganization will affect staffers in a range of functions including the company’s commercial teams, R&D, medical affairs and manufacturing. Besides the layoffs, the drugmaker also reported a fire in India.

February 26, 2026

News·Solutions

AbbVie advances US expansion with $380M for 2 new North Chicago API plants

The new plants are the latest in a string of recent investments AbbVie has made in U.S. manufacturing, filling out the company’s plan to infuse $100 billion into its American operations over

February 23, 2026

News·Solutions

CDMO Bora locks in 5-year, $250M production agreement with GSK

With a productive working relationship between the two companies already well established, Bora Pharmaceuticals is renewing a $250 million global manufacturing agreement with British drugmaker GSK.

February 23, 2026

News·Solutions

Catalent cuts staff by 96 in another round of layoffs in Maryland

Catalent is cutting more roles at its gene therapy manufacturing facility in Harmans, Maryland. This round of layoffs will affect 93 employees at the Harmans facility and three more in nearby Baltimore.

February 20, 2026

News·Solutions

Roche looks to divest its former blockbuster antibiotic amid EU generics woes

After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production facility near its headquarters in

February 20, 2026

News·Solutions

Trump’s tariff threats, measured by manufacturing

In this episode of “The Top Line,” Fierce Pharma’s Fraiser Kansteiner speaks with Atradius’ Brady McKinney about how tariff pressures drove a 2025 manufacturing surge in pharma and why production is expected

February 19, 2026

News·Solutions

Manus Bio scores $15M US contract for domestic supply of flu drug component

Synthetic biology specialist Manus Bio has scored a $15 million contract from the U.S. government to create a domestic supply source for shikimic acid, a key starting material used in the production

February 19, 2026

News·Solutions

J&J fleshes out US investment plan, telegraphing $1B cell therapy plant and 500 new jobs in PA

With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion plans that are aimed, at least in part, at abating the

February 18, 2026

News·Solutions

Recipharm focuses footprint with sale of Israel API plant, new CDMO partnership

As Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai Immunotherapeutics.

February 18, 2026

News·Solutions

Previous 1 … 9 10 11 12 13 … 22 Next

Go toTop